Worldwide Medical Civil Money Penalties Sought For DOA Test Marketing
This article was originally published in The Tan Sheet
FDA affirmed its regulatory authority over home-use drugs-of-abuse (DOA) assays in an October 1999 letter to Worldwide Medical that preceded its recent civil money penalty action against the firm, the agency says.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC